82 filings
Page 4 of 5
8-K
0ensut 2ivnzh
13 Jul 20
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon
6:05am
8-K
r42fpein be0
1 Jun 20
Departure of Directors or Certain Officers
8:04am
8-K
n1o v0y9ri2
21 May 20
Submission of Matters to a Vote of Security Holders
8:17am
8-K
qnd1hy
13 May 20
Equillium Reports First Quarter 2020 Financial Results
4:10pm
8-K
mln4oj12gequed34vcp
24 Apr 20
Departure of Directors or Certain Officers
4:30pm
8-K
q6ynoh6jpn xqaov
30 Mar 20
Entry into a Material Definitive Agreement
4:15pm
8-K
yerd4
26 Mar 20
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
4:10pm
8-K
nvirfyfmtqyyv
12 Dec 19
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to
7:05am
8-K
wi5ka
27 Nov 19
Other Events
4:08pm
8-K
wvcp279e7 sqm2i3
12 Nov 19
Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights
4:10pm
8-K
qlzygiq36 atdo3pl
1 Oct 19
Entry into a Material Definitive Agreement
4:10pm
8-K
1onv2v42107
12 Aug 19
Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
4:10pm
8-K
q6h957untzgvevspesw5
12 Jun 19
Submission of Matters to a Vote of Security Holders
4:10pm
8-K
d8q8gjzlk
13 May 19
Equillium Reports First Quarter 2019 Financial Results and Recent Highlights
4:15pm
8-K
pcx vpblgzz2o
1 May 19
Regulation FD Disclosure
12:00am
8-K
2lg416x3
27 Mar 19
Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
4:08pm
8-K
pj3 666wmi
26 Feb 19
Results of Operations and Financial Condition
4:05pm
8-K
28k zibku
20 Feb 19
Material Modifications to Rights of Security Holders
4:08pm
8-K
tqvt3
20 Dec 18
Departure of Directors or Certain Officers
4:05pm
8-K
upsmw27qquvda 4o
15 Nov 18
Equillium Reports Third Quarter 2018 Financial Results and Recent Highlights
4:20pm